As advised via PHARMAC proposal of 16 October 2018 and the notification of PHARMAC decision of 20 December 2018 there is to be a change in the listing and future sole supply of Atazanavir Sulphate Capsules.

New listing from 1 April 2019

Atazanavir Sulphate  Teva  Caps 150 mg 60                                              Pharmacode 2560461                                 Schedule price $141.68

Atazanavir Sulphate  Teva  Caps 200 mg 60                                              Pharmacode 2563118                                 Schedule price $188.91

Incumbent listing

Reyataz Cap 150 mg 60                                                                                                          Pharmacode 2234319                               Schedule price $568.34

Reyataz Cap 200 mg 60                                                                                                          Pharmacode 2234327                               Schedule price $757.79

Reference pricing will apply from 1 June 2019.

HSS (Hospital Supply Status) commences 1 June 2019.

CSS (Community Supply Status) commences 1 September 2019.

Brand switch fee to apply from 1 June 2019 to 30 August 2019.

As of the date of this notification ProPharma / PWR cannot accept Reyataz Cap 150 mg &b 200 mg for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted. But be very wary of holding stock.

Benefit of staying with incumbent until 30 May 2019:-

Reyataz Cap 150 mg 60 : – Average dispensing is 60 tablets. Therefore 1 x 60 @ $568.34 x 4% = $18.7336 plus 1 x $0.253 (pack fee) giving you $18.9866

Compared to $141.68 x 3% = $4.2504 plus 1 x $0.253 (pack fee) giving you $4.5034

Reyataz Cap 200 mg 60 : – Average dispensing is 60 tablets. Therefore 1 x 60 @ $757.79 x 4% = $30.3116 plus 1 x $0.253 (pack fee) giving you $30.5646

Compared to $188.91 x 4% = $7.5564 plus 1 x $0.253 (pack fee) giving you $7.8094

You MUST manage your stock so that you have ZERO stock at time of reference pricing being 1 June 2019. Failure to do so could prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close